Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

776.38
8,254,426

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline

by Zacks Equity Research

Radius (RDUS) posts a y/y wider Q1 loss and misses revenue estimates.

Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track

by Zacks Equity Research

Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.

Should Invesco Dynamic Large Cap Growth ETF (PWB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PWB

United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up

by Zacks Equity Research

United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE

by Kinjel Shah

Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.

Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FVD

Eli Lilly (LLY) Beats on Q1 Earnings, Ups Sales View, Stock Rises

by Zacks Equity Research

Eli Lilly (LLY) beats first-quarter estimates for both earnings and sales and ups its sales outlook for 2022. The stock rises in pre-market trading.

GDP Declined in First Quarter

by Zacks Equity Research

GDP Declined in First Quarter

Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute

by Zacks Equity Research

Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.

Mark Vickery headshot

Q1 GDP Negative; Q1 Earnings Beats from CAT, LLY, MCD

by Mark Vickery

GDP reported the first negative quarter since Q2 2020, which was considered the "heart" of the pandemic.

Eli Lilly (LLY) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of 12.93% and 3.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More

by Zacks Equity Research

Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.

Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.

Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) first-quarter sales.

Thermo Fisher (TMO) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

The negative impact of COVID-19 in the form of supply issues and staffing shortages are expected to have deterred growth in a few areas within the Analytical Instruments business of Thermo Fisher (TMO).

The Zacks Analyst Blog Highlights Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals

by Zacks Equity Research

Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals have been included in this Analyst Blog.

Eli Lilly (LLY) Stock Moves -1.13%: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $289.61 in the latest trading session, marking a -1.13% move from the prior day.

Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy

by Kinjel Shah

Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.

Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Robust global demand for Oncotype DX and increased Cologuard orders are likely to have driven Exact Sciences' (EXAS) Q1 performance.

AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag

by Zacks Equity Research

FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).

Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA

by Zacks Equity Research

Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.

Has Brickell Biotech (BBI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Brickell (BBI) and Eli Lilly (LLY) have performed compared to their sector so far this year.

J&J (JNJ) Beats on Q1 Earnings, Suspends COVID Jab Sales View

by Zacks Equity Research

J&J (JNJ) reports mixed first-quarter results. It beats estimates for earnings but misses the same for sales. It cuts full-year outlook.